- Home
- » Tags
- » Amivantamab
Top View
- Medical Benefit Injectable Drugs | Kaiser Permanente Washington
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-Cmet Bispecific Antibody, In
- Research and Clinical Landscape of Bispecific Antibodies for The
- EGFR Positive (EGFR+) Lung Cancer? ABOUT LUNG BIOMARKERS
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- Specialty Injectables Prior Authorization List
- 1 Effective August 1, 2021
- Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/ Cmet Bispecific
- A Potent Novel EGFR/C-MET Bispecific Antibody Therapy for EGFR-Mutated Non-Small Cell Lung Cancer
- (Amivantamab-Vmjw) NCCN Compendium Communication – May 2021
- Connecticare Commercial Connecticare Commercial J7192 Advate (Factor VIII)
- Molecular Features As Drug Targets and Antibody-Drug Conjugates for Therapy Hang-Ping Yao1,2*, Xiang-Min Tong3*, Rachel Hudson4,5 and Ming-Hai Wang1,2,4,5*
- Oncology Medications Policy (1403)
- CHMP Agenda of the 25-29 January 2021 Meeting
- Precision Medicine in Oncology: a Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Mandatory Specialty Drug List
- Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of the Art and Future Directions
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- PDF of Antibody News
- Services That Require Precertification Standard Precert Effective: 7/1/2021 This Applies to Elective, Nonemergency Services
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
- Announced That the US Food and Drug Administration
- Form 10-K Halozyme Therapeutics, Inc
- Antibody News You Should Know July 1 - 15, 2020
- Specialty Pipeline Monthly Update June 2021
- EGFR Exon 20 Insertions in Advanced Non-Small Cell Lung Cancer a New
- EGFR Exon 20 Insertions in Advanced Non-Small Cell Lung Cancer a New
- Antibodies to Watch in a Pandemic
- A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
- New Drug Approval
- 5.01.603 Epidermal Growth Factor Receptor (EGFR) Inhibitors
- 07/23/2021 Crosswalk Header Definition Additional
- Specialty Pipeline MONTHLY UPDATE
- Publication Agenda CHMP 07-10 December 2020
- Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/Cmet Bispecific
- Genmab Announces That Janssen Has Submitted a Biologics License Application to U.S
- Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/ Cmet Bispecific